Tetra Gallops on Resumption of Cancer Trials

Tetra Gallops on Resumption of Cancer Trials

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, April 9, 2019

The fight against cancer is a never-ending one, and Tetra Bio-Pharma Inc. (TSX-Venture:TBP) is building up the weaponry for its latest salvo.

The Ottawa-based drug maker announced Tuesday it is ready to resume its Phase 3 clinical program in advanced cancer pain patients.

The SERENITY© Study will use a vaporizer, a Health Canada-approved Class 2 medical device as a delivery mechanism which is more acceptable to hospitals and palliative care centres. Tetra’s new drug formerly referred to as PPP-001 will be investigated in the SERENITY © Study under the commercial label, CAUMZ.

According to CEO Guy Chamberland, “With great challenge comes great opportunity and what we are now able to deliver is a better and more reliable product.”

As for the company’s shares, they rocketed six cents, or 9.4%, Tuesday afternoon, to 70 cents, on volume of 911,000 shares. 

 


Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares of Biopharma Up After News of Uplisting
Expansion into Taiwan Markets Is Helping Shares of this Blockchain Firm
Mixed Shelf Filing Gives Micro Cap Delayed Boost
Most Popular
FREE Newsletter


Back to Top